Related Experiment Video
Updated: Aug 11, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
Frusemide/amiloride combination ('Frumil') in heart failure: an open, multi-centre study in general practice
Current Medical Research and Opinion
|January 1, 1984
Summary
This study found that a combination tablet of frusemide and amiloride effectively treated edema in heart failure patients. Most patients showed significant improvement with good tolerability over three months.
Area of Science:
- Cardiology
- Pharmacology
- General Practice
Background:
- Edema is a common symptom associated with heart failure.
- Effective management of edema is crucial for improving patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and tolerability of a combination tablet containing frusemide and amiloride in patients with heart failure-related edema.
- To assess the impact of this combination therapy on edema severity, body weight, and overall clinical status.
Main Methods:
- An open-label study involving 95 general practice patients with heart failure-related edema.
- Patients received 1-2 tablets (40 mg frusemide/5 mg amiloride) daily for three months.
- Efficacy assessed via physician scores for edema, pulmonary crepitations, body weight, and global impression; patient symptom diaries were also used.
Main Results:
- 93.7% of patients (89/95) were classified as excellent, good, or adequate responders.
- Significant improvements were observed in edema severity scores, pulmonary crepitations, and body weight.
- The treatment demonstrated good tolerability, with only 4 patients withdrawn due to adverse effects; no significant changes in clinical chemistry were noted.
Conclusions:
- The combination tablet of frusemide and amiloride is an effective and well-tolerated treatment for edema in heart failure patients.
- This therapeutic approach offers a valuable option for managing fluid overload in heart failure within a general practice setting.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.